ArticleEmerging microbes & infections2024
Efficacy of genotype-matched vaccine against re-emerging genotype V Japanese encephalitis virus.
Article in Emerging microbes & infections, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 19 citations in OpenAlex.
- Importation risks and local transmission of Japanese encephalitis virus in Taiwan.One health (Amsterdam, Netherlands) · 2026Article
- Recombinant Japanese Encephalitis Virus Envelope Antigen Presented on CoPoP Liposomes Elicits Cellular Immunity and Protects Mice From Lethal Challenge.Immune network · 2026Article
- NADFASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2026Article
- Evaluation of protective efficacy of an inactivated Japanese encephalitis virus genotype Ⅴ strain in mice.NPJ vaccines · 2026Article
- Thioester-Containing Protein TEP27 inInternational journal of molecular sciences · 2025Article
- Advances and Challenges in Vaccination and Therapeutic Strategies Against Japanese Encephalitis Virus.Pathogens (Basel, Switzerland) · 2025Review
- The hidden threats posed by Japanese encephalitis virus genotype V.Journal of virology · 2025Review
- Review
- Genotype-Specific Vector Competence ofViruses · 2025Article
- Managing Japanese Encephalitis Virus as a Veterinary Infectious Disease Through Animal Surveillance and One Health Control Strategies.Life (Basel, Switzerland) · 2025Review
- From Antibodies to Immunity: Assessing Correlates of Flavivirus Protection and Cross-Reactivity.Vaccines · 2025Review
- Characterization of genotype V Japanese encephalitis virus isolates from Republic of Korea.Emerging microbes & infections · 2024Article
- Characterization of a Small Plaque Variant Derived from Genotype V Japanese Encephalitis Virus Clinical Isolate K15P38.Journal of microbiology and biotechnology · 2024Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Japanese encephalitis (JE), caused by the Japanese encephalitis virus (JEV), is a highly threatening disease with no specific treatment. Fortunately, the development of vaccines has enabled effective defense against JE. However, re-emerging genotype V (GV) JEV poses a challenge as current vaccines are genotype III (GIII)-based and provide suboptimal protection. Given the isolation of GV JEVs from Malaysia, China, and the Republic of Korea, there is a concern about the potential for a broader outbreak. Under the hypothesis that a GV-based vaccine is necessary for effective defense against GV JEV, we developed a pentameric recombinant antigen using cholera toxin B as a scaffold and mucosal adjuvant, which was conjugated with the E protein domain III of GV by genetic fusion. This GV-based vaccine antigen induced a more effective immune response in mice against GV JEV isolates compared to GIII-based antigen and efficiently protected animals from lethal challenges. Furthermore, a bivalent vaccine approach, inoculating simultaneously with GIII- and GV-based antigens, showed protective efficacy against both GIII and GV JEVs. This strategy presents a promising avenue for comprehensive protection in regions facing the threat of diverse JEV genotypes, including both prevalent GIII and GI as well as emerging GV strains.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.